Skip to content

To evaluate effect of Tiladi Kwatha Orally & Shatpushpa Siddha Taila Nasya in the treatment of Pushpaghni (PCOS)

"CLINICAL STUDY OF TILADI KWATHA ORALLY AND SHATPUSHPA SIDDHA TAILA NASYA IN THE MANAGEMENT OF PUSHPAGHNI ? (PCOS) - CSTKSTN

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/055952
Enrollment
30
Registered
2023-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

None listed

Sponsors

Post Graduate Institute of Ayurved, Jodhpur Rajasthan
Lead Sponsor
Dr Sanoor Bano
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed cases of PCOS by the Rotterdam criteria. 2.Age: Patients aged between 16-40 years. 3. The patients who are fit for the Nasya procedure were only considered for the study. 4. Patients willing for Informed consent.

Exclusion criteria

Exclusion criteria: •Patients having any other disease causing oligomenorrhea and anovulation excluding PCOD on the above criteria. •Patients using oral contraceptive pills. •Pregnant and lactating women. •Patients suffering from thyroid abnormalities, Hyperprolactinemia, adrenal hyperplasia etc. •Patients with any organic reproductive system abnormalities like hydrosalpinx, endometriosis, fibroid uterus, carcinoma of reproductive organ and sexually transmitted disease (STDs), Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg). •Systemic disorders like-uncontrolled diabetes mellitus, chronic liver disease, renal disorder, Uncontrolled hypertension, Diagnosed case of any type of malignancy. •Patients who are contraindicated for Nasya like, Nasal polyp etc.

Design outcomes

Primary

MeasureTime frame
1.Assessment for Menstrual abnormality (Oligomenorrhea) 2.Assessment for Hypomenorrhea 3.Assessment for Menorrhagia 4.Pain associated with Menstruation 5.Assessment of Acne (according to acne grading) 6.Assessment of Hirsutism (on the basis of site) Timepoint: for 8 weeks

Secondary

MeasureTime frame
â?¢Percentage improvement in reduction of ovarian size, volume, stromal pattern â?¢ Percentage improvement in biochemical values. â?¢Percentage improvement in hormonal assays. â?¢Weight reduction as assessed by reduction in Body weight, BMITimepoint: 60 DAYS

Countries

India

Contacts

Public ContactDr Sanoor Bano

Post Graduate Institute of Ayurveda, DSRRAU Jodhpur

vd_rashmi11@yahoo.com9166607559

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026